Clinical trials: Renal Transplant Recipient
Kidney Transplantation
Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients
This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation, when combined with tacrolimus for the first 3 months and with myfortic thereafter.
- Trial name
- NCT00403416
- Testing
- AEB071, Mycophenolic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 215 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant
Randomized Study to Reduce Calcineurininhibitor Toxicity in Pediatric and Adolescent Kidney Transplant Recipients
The purpose of this study is to determine if a safe reduction of cyclosporine A in pediatric and adolescent patients with stable renal graft function, reduces signs of calcineurin-inhibitor toxicity.
- Trial name
- Recaltox (NCT00663455)
- Testing
- Reduction of cyclosporine A (CSA)-dosing
- Where
- 10 sites in Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Rejection Acute Renal, Rejection Chronic Renal
Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients
This is a multinational, multi-center, observational cohort study. Kidney allograft rejection is poorly detected by standard-of-care biomarkers.
- Conditions
- Rejection Acute Renal, Rejection Chronic Renal, Transplantation, Kidney Rejection Transplant
- Trial name
- VALiDATE (NCT07805343)
- Testing
- Donor-derived cell-free DNA
- Where
- 25 sites in United States, Belgium and 6 more
- Volunteers
- 5,000 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Organ Donation, Liver Transplantation
EPI-STORM: Cytokine Storm in Organ Donors
Kidney and liver transplantation are the treatment of choice and are often the last therapeutic option offered to patients with chronic renal and liver failure.
- Conditions
- Organ Donation, Liver Transplantation, Kidney Transplantation, Graft Dysfunction
- Trial name
- EPI-STORM (NCT03786991)
- Testing
- No intervention
- Where
- 4 sites in Canada
- Volunteers
- 105 people
- Sponsor
- Université de Sherbrooke
Kidney Diseases, Kidney Transplant; Complications
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in…
- Conditions
- Kidney Diseases, Kidney Transplant; Complications, COVID-19, Vaccine Adverse Reaction
- Trial name
- NCT05483725
- Testing
- Booster dose of mRNA vaccine
- Where
- Czechia
- Volunteers
- 108 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Kidney Transplantation, Chronic Kidney Disease
Calcineurin Free Immunosuppression in Renal Transplant Recipients
The main purpose of this study is to obtain preliminary information on the efficacy, safety and cost of two regimens, Rapamycin / MMF / steroid therapy and Cyclosporine A Neoral / MMF / steroid therapy, used in the prevention of…
- Trial name
- NCT00812123
- Testing
- Sirolimus, Cyclosporine A, Prednisone
- Where
- Switzerland
- Volunteers
- 127 people
- Sponsor
- University Hospital, Basel, Switzerland
Kidney Transplantation, Liver Transplantation
Quality of Life in Pediatric Transplant Patients
The goal of this study is to compare parent and child perceptions of wellness and vulnerability in children who have undergone solid organ transplant.
- Conditions
- Kidney Transplantation, Liver Transplantation, Heart Transplantation
- Trial name
- NCT00678002
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Medical College of Wisconsin
Transplantation, Kidney Transplantation
Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
The purpose of this study is to understand the pharmacokinetics of sirolimus tablets in different regimens in newly renal transplant patients, and the effect of dosage form conversion on the concentration of sirolimus in stable…
- Conditions
- Transplantation, Kidney Transplantation, Immunosuppression
- Trial name
- NCT00166842
- Testing
- sirolimus, cyclosporine, tacrolimus
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients
After a kidney or a kidney-pancreas transplant, some patients may face problems with their new organs. This happens because the body sometimes makes a mistake and tries to get rid of the organ. This problem is called rejection.
- Trial name
- TACKLE-IT (NCT06474273)
- Testing
- Methylprednisolone, Prednisone
- Where
- 30 sites in Australia, Canada and 1 more
- Volunteers
- 540 people
- Sponsor
- University of Sydney
Metabolic Effects, Immunosuppressive Agents
Impact of SCFA Supplementation on Metabolic Profiles in Serum and Urine of Kidney Transplant Recipients.
This is a randomized, double-blind, placebo-controlled clinical trial evaluating the impact of short-chain fatty acid (SCFA) supplementation on the serum and urinary metabolome in stable kidney transplant recipients.
- Conditions
- Metabolic Effects, Immunosuppressive Agents, Adverse Events, Imunological Effects
- Trial name
- METAKID (NCT06951581)
- Testing
- Short Chain Fatty Acid
- Where
- Slovakia
- Volunteers
- 41 people
- Sponsor
- University Hospital, Martin
Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC)
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
This is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell…
- Conditions
- Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney Transplant
- Trial name
- CONTRAC-2 (NCT07715734)
- Testing
- Cemiplimab, Prednisone, Sirolimus
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine
Kidney Transplant, Hepatitis C
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection
- Conditions
- Kidney Transplant, Hepatitis C, HCV
- Trial name
- NCT03801707
- Testing
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Ohio State University
Glucose Intolerance
Sitagliptin in Renal Transplant Recipients
The major cause of premature death in renal transplant recipients is cardiovascular disease. Sitagliptin stimulates insulin secretion and inhibits glucagon release, two central mechanisms in PTDM by interaction with a hormone…
- Trial name
- NCT00740363
- Testing
- sitagliptin
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- University of Oslo School of Pharmacy
BK Virus Nephropathy After Kidney Transplantation
Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.
BK virus nephropathy (BKVN), a consequence of the strong immunosuppressive therapy given after kidney transplantation, represents a growing problem in the kidney transplant (KT) setting.
- Trial name
- BK EVER (NCT03216967)
- Testing
- everolimus
- Where
- 15 sites in France
- Volunteers
- 130 people
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplant Recipients
COVID-19 Protection After Transplant Pilot Study
Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who…
- Trial name
- CPAT (NCT04969263)
- Testing
- BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Transplantation
Optimal Dose of Anti-lymphocyte Globulin in Kidney Transplant Recipients With Low Immunological Risk
Antithymocyte globulins (ATG) are the gold standard of induction therapies and are currently used to prevent or treat acute rejection in solid organ transplantation.
- Trial name
- ODORAT (NCT06744400)
- Testing
- Grafalon® administered during 5 consecutive days at 2 mg/kg/j, Grafalon® administered during 5 consecutive days at 1 mg/kg/j, Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Kidney Failure, Graft vs Host Disease
Study Evaluating Sirolimus in Kidney Transplant Recipients.
Renal function at 12 months assessed by calculated creatinine clearance.
- Trial name
- NCT00167947
- Testing
- Cyclosporine, Steroids, Rapamune (Sirolimus)
- Where
- 14 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Transplant Infection, BK Virus Infection
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient
BK virus infection is one of the causes of renal allograft loss in the current era. Reduction of immunsuppression is the only intervention that prooved to be effective in treating of BK virus in kidney transplant recipient.
- Trial name
- ELF (NCT04542733)
- Testing
- Everolimus, reduced dose tacrolimus and Leflunomide
- Where
- Thailand
- Volunteers
- 50 people
- Sponsor
- King Chulalongkorn Memorial Hospital
Kidney Transplantation, BK Virus
IVIg to Treat BK Viremia in Kidney Transplant Recipients
The overall goal of this study is to rapidly improve clearance of BK viremia with Immunoglobulin (Privigen®) thereby decreasing the potential for formation of alloantibodies in renal transplant recipients that have had…
- Conditions
- Kidney Transplantation, BK Virus, Isoantibodies
- Trial name
- NCT02659891
- Testing
- IVIg
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Renal Transplant, Atherosclerosis
Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
The purpose of this study is to determine the: Natural history of calcification posttransplantation Natural history of BMC following renal transplantation Reverse correlation between calcification score and aortic calcifications…
- Conditions
- Renal Transplant, Atherosclerosis, Arterial Stiffness
- Trial name
- ASCIT (NCT00547040)
- Testing
- no intervention
- Where
- Belgium
- Volunteers
- 304 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven